2019
IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA
Sun M, Orpilla J, Contreras E, Treger J, Molaie D, Tsang J, Antonios J, Wang A, Liau L, Prins R, Everson R. IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA. Neuro-Oncology 2019, 21: vi129-vi130. PMCID: PMC6847786, DOI: 10.1093/neuonc/noz175.542.Peer-Reviewed Original ResearchTCR-transduced T cellsNY-ESO-1 expressionNY-ESO-1Targeting NY-ESO-1Systemic adoptive transferAdoptive transferT cellsNY-ESO-1 mRNA expressionT cells in vitroSurvival benefit in vivoAdoptive transfer immunotherapyIncreased overall survivalIn vitro cytolysisMeningiomas in vitroHigher-grade meningiomasIn vivoReal-time cell analyzer systemAugment immunotherapyBenefit in vivoTumor cytolysisCT antigensImmunotherapeutic strategiesNSG miceOverall survivalImmunotherapy development
2015
Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma
Everson R, Antonios J, Lisiero D, Soto H, Scharnweber R, Garrett M, Yong W, Li N, Li G, Kruse C, Liau L, Prins R. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology 2015, 18: 368-378. PMID: 26330563, PMCID: PMC4767237, DOI: 10.1093/neuonc/nov153.Peer-Reviewed Original ResearchConceptsNY-ESO-1NY-ESO-1-specific T cellsCells treated with decitabineDiffusely infiltrating tumor cellsAdoptive T cell therapyIntracranial human glioma xenograftsT-cell therapyDemethylating agent decitabineTumor rejection antigensGlioma-bearing miceSignificant survival benefitSquamous cell carcinomaPhenotype of lymphocytesT cell traffickingInfiltrating tumor cellsIdeal treatment modalityReal-time cytotoxicity assayHuman glioma xenograftsHuman glioblastoma cell culturesLong-term survivalClinically feasible strategyLong-term survival of animalsIn vitro treatmentTreatment of glioblastomaGlioblastoma cell cultures